Early expression and high prevalence of islet autoantibodies for DR3/4 heterozygons and DR4/4 homozygous offspring of parents with Type I diabetes: The German BABYDIAB study

Aims/hypothesis. Islet autoantibodies precede the clinical onset of Type I (insulin-dependent) diabetes mellitus. The cumulative development of such a utoantibodies in infants followed from birth and in particular infants with high-risk HLA genotypes is poorly defined, but such information is essenti al to design trials to prevent islet autoimmunity. Methods. HLA genotypes were determined in offspring of parents with Type I diabetes who were followed from birth for at least 2 years (median followup : 3.1 years) and who were characterised for the expression of insulin, GAD6 5, IA-2 and islet cell autoantibodies at birth, 9 months, 2 and 5 years of age. Results. The HLA genotypes DRB1*03/04(DQB1*57non-Asp) and DRB1*04/04(DQB1*5 7non-Asp) were present in 7.1 % and 5.0 % of offspring of parents with Type I diabetes. The frequency of both genotypes was increased in offspring who developed islet autoantibodies within the first 2 years of life (27.3 % vs 5.5 %, odds ratio 6.3 [p = 0.002] and 22.7 % vs 4.2 %, odds ratio 6.6 [p = 0.003]) and half of all offspring who developed antibodies had these genot ypes. Other genotypes were not associated with an increase in risk. By life -table analysis, the cumulative risk of developing islet autoantibodies by the age of 2 years was 20 % (95 % CI 9.4,30.6) for offspring carrying eithe r the DRB1*03/04(DQB1 *57non-Asp) or the DRB1*04/04(DQB1*57non-Asp) genotyp e compared with 2.7 % (95 % CI 1.2,4.2) for offspring without these genotyp es (p < 0.0001). Conclusion/interpretation. These data show that early appearance of islet a utoantibodies is remarkably frequent for DR3/4 heterozygous and DR4/4 homoz ygous offspring and indicate that primary prevention could be considered on ce available in an offspring cohort selected for these genotypes.